EyePoint completes Phase 3 LUGANO enrollment for DURAVYU wet AMD; topline data mid-2026

EyePoint, Inc.

Over 400 patients enrolled/randomized in seven months, one of fastest Phase 3 wet AMD trials.
LUCIA trial 60% randomized; enrollment completion expected Q3 2025.
Topline 56-week LUGANO data mid-2026; LUCIA data in H2 2026.
Phase 3 trials are randomized, double-masked, non-inferiority vs. aflibercept; DURAVYU dosed every 6 months.
DURAVYU is sustained-delivery vorolanib (TKI); potential first sustained-release TKI for wet AMD.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.